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Abstract 
Toxoplasmosis is a parasitic zoonotic disease caused by Toxoplasma gondii that afflicts humans worldwide and wild 
and domestic warm‑blooded animals. In immunocompetent individuals, the acute phase of infection presents tran‑
sient low or mild symptoms that remain unnoticed. In immunocompromised patients, T. gondii is a life‑threatening 
opportunistic infection, which can result from the reactivation of latent infection or primary infection. Moreover, con‑
genital toxoplasmosis, which results from the transplacental passage of tachyzoites into the fetus during a pregnant 
primary infection, can lead to miscarriage, stillbirth, or ocular and neurologic disease, and neurocognitive deficits in 
the newborns. Thus, the present review aims to address the current knowledge of T. gondii infection and toxoplasmo‑
sis in Africa and especially in Mozambique, stressing the importance of identifying risk factors and promote awareness 
among the health care providers and population, assessing the gaps in knowledge and define research priorities. 
In Mozambique, and in general in southern African countries, clinical disease and epidemiological data have not 
yet been entirely addressed in addition to the implications of T. gondii infection in immunocompetent individuals, 
in pregnant women, and its relation with neuropsychiatric disorders. The main gaps in knowledge in Mozambique 
include lack of awareness of the disease, lack of diagnostic methods in health facilities, lack of genetic data, and lack of 
control strategies.
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Background
Toxoplasmosis is a zoonotic disease caused by the para-
site Toxoplasma gondii, a cosmopolitan intracellular 
protozoan. This parasite can infect a wide range of warm-
blooded animals, including humans who act as interme-
diate hosts, supporting the asexual phase of the T. gondii 
life-cycle. Cats and wild felines have been considered 
definitive hosts since the sexual reproductive phase of 
the T. gondii life-cycle is restricted to these animals. Peo-
ple may become infected through the ingestion of raw or 
undercooked meat containing cyst, or by food and water 
contaminated with highly resistant and easily dispersed 
T. gondii oocysts from feline feces [1–3]. It seems that 
one to ten sporulated oocyst is enough to cause infec-
tion, giving rise to the asexual phase of the T. gondii life-
cycle [4, 5]. Infection also can be acquired by cysts after 
organ transplantation and by tachyzoites, which can 
cross the placenta during pregnancy, causing congeni-
tal toxoplasmosis and through blood transfusion [1, 2, 
6]. Globally, it is anticipated that one-third of the world 
population is infected with T. gondii and that the preva-
lence of infection varies between 10–80%, depending on 
local culture, eating habits, and climate [6–8]. In South 
America and tropical Africa, the prevalence of the dis-
ease is very high, with more than 50% of people infected, 
while in Europe, North America, and Southeast Asia the 
prevalence rates range from 7% to 50% [3, 9, 10]. Stud-
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such as Zambia, South Africa, Eswatini (former Swazi-
land), Zimbabwe, Angola, Namibia, Tanzania, Madagas-
car, Uganda, Kenya, Ethiopia, and Mozambique, indicate 
prevalence of T. gondii infection that ranges from 4% to 
93% in the general population [11–13]. Signs, symptoms, 
and the severity of T. gondii infection differs according to 
the immune status of the individual, the age in which the 
infection was acquired, and the genotype of the parasite 
involved [2, 3, 14–16]. In immunosuppressed patients 
due to human immunodeficiency virus (HIV) or immu-
nosuppressive therapy, toxoplasmosis is considered a 
life-threatening parasitic disease. Despite the growing 
numbers of drug-immunosuppressed patients and the 
few available studies, these patients can also be at risk of 
developing toxoplasmosis, in particular, the transplanted 
patients [17, 18]. Toxoplasma gondii genotyping studies 
recognize three major subtypes identified as subtype I, 
subtype II, and subtype III. Altogether they account for 
95% of isolates from North America and Europe, each 
leading to differences in disease severity [2, 3]. In these 
regions, the majority of cases of congenital toxoplasmosis 
and toxoplasmosis infection in HIV immunosuppressed 
individuals are mainly caused by type II strains. How-
ever, most of the isolates from South America, Africa, 
and Asia do not fit into the three major lineages, except 
type III, which is really cosmopolitan and commonly 
found in animals [2, 19]. Atypical, exotic, recombinant, 
or non-archetypal genotypes were found in other con-
tinents and the characterization of the strains by multi-
locus polymerase chain reaction-restriction fragment 
length polymorphism (PCR-RFLP), using ten genetic 
markers revealed 18 different genotypes. Together they 
account for 5% of infections, generating more virulent 
parasites due to its genetic diversity and the consequent 
increase of disease severity [3, 14, 20]. A large meta-
analysis and a prospective cohort study showed a higher 
risk of ocular Toxoplasmosis in children from Brazil and 
Colombia than in European children (47% versus 14%). 
Furthermore, ocular lesions were large, numerous, and 
more likely to affect the retina that according to several 
authors may be explained by the predominance of atypi-
cal T. gondii strains in Latin America [21–23]. There 
are multiple tools available for the diagnosis of T. gondii 
infection, particularly serological, molecular, and imag-
ing techniques. Serological assays allow the detection of 
T. gondii specific antibodies, immunoglobulin M (IgM) 
and immunoglobulin G (IgG). Usually, these tests possess 
high sensitivity and specificity due to antigen standardi-
zation and good assay reproducibility in immunocom-
petent individuals [24]. Molecular biological tests based 
on polymerase chain reaction (PCR) allow detection of 
parasite deoxyribonucleic acid (DNA) and identification 
of genetic variants, while imaging techniques, such as 
computed tomography and magnetic resonance imag-
ing, that have been employed to evaluate expansive brain 
lesions of cerebral toxoplasmosis, present high sensitiv-
ity, but low specificity and should be used in combination 
with other diagnostic methodologies [2, 3, 25–27]. More 
recently, the use of recombinant antigens has been pro-
posed as an alternative to conventional serological assays 
because of its limited value, especially in immunosup-
pressed patients [3, 28, 29]. Patients with confirmed toxo-
plasmosis have multiple treatment options, depending 
on immune competence and disease severity. However, 
most of the drugs used to treat toxoplasmosis are effec-
tive against tachyzoites, the acute morphological form 
of T. gondii, but do not seem to eradicate the encysted 
bradyzoites forms (chronic phase). Pyrimethamine com-
bined with sulfadiazine and trimethoprim-sulfamethoxa-
zole combined with spiramycin are the main choice for 
the clinical treatment of toxoplasmosis [30]. To prevent 
parasite transmission from a pregnant woman to her 
fetus spiramycin is the drug of choice. For congenital 
toxoplasmosis, pyrimethamine and sulfadoxine together 
with folinic acid to prevent bone marrow suppression are 
the recommended drugs to treat the newborn, while a 
combination of pyrimethamine, azithromycin, and corti-
costeroids is recommended for treating ocular toxoplas-
mosis [27]. Despite the limited reports available on the 
relative importance of toxoplasmosis in Africa and par-
ticularly in Mozambique, where the studies on human T. 
gondii infection are scarce, this review aims to: (i) sum-
marize and critically examine the most relevant aspects 
of Toxoplasma infection and toxoplasmosis in Africa and, 
specifically in Mozambique; (ii) identify gaps of knowl-
edge; (iii) highlight the research opportunities and reflect 
on its implications for the population well-being and for 
the socio-economic development of Mozambique.
Toxoplasmosis in immunosuppressed patients
In HIV-immunosuppressed patients and individuals 
undergoing cancer treatment or organ transplantation, 
Toxoplasma infection can become a severe opportun-
istic disease, which can result from a primary infec-
tion, but most of the time results from reactivation of 
an earlier acquired infection. Reactivation of brady-
zoites (the dormant forms of this parasite) and dif-
ferentiation in tachyzoites occurs as a consequence of 
patient’s reduced immunocompetence, leading to tissue 
injury [31, 32]. In sub-Saharan Africa, where the major-
ity (70%) of HIV-infected people live [33], patients are 
commonly diagnosed with HIV after developing cerebral 
toxoplasmosis. It is estimate that this parasitic disease 
is indicative of HIV infection in 35% of patients and an 
acquired immunodeficiency syndrome (AIDS) defining 
event in 75% of the cases [3, 32, 34, 35]. With access to 
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combination antiretroviral therapy (cART), the incidence 
of encephalitis caused by T. gondii in  HIV+ patients have 
reduced dramatically. Before the anti-retroviral treat-
ment era, rates of cerebral toxoplasmosis in the USA 
and the UK ranged between 16 and 40%, in Brazil 50 
to 80%, in France 75 to 90%, and in Spain, it was about 
60% [36]. In Ethiopia, a serological study in HIV-infected 
patients found Toxoplasma infections ranging from 3% 
to 97% [37, 38]. In Uganda anti-T. gondii antibodies were 
detected in 54% of  HIV+ patients and 23% present para-
sites in the peripheral blood [39], pointing for an acute 
infection that possibly represents a reactivation. On the 
contrary, in Johannesburg (South Africa), the prevalence 
of latent Toxoplasma infection was lower in HIV infected 
patients, ranging between 8% and 18% [40, 41]. Moreo-
ver, in Nigeria, 85.5% of HIV/AIDS patients that were 
under cART present latent Toxoplasma infection (sero-
positive for T. gondii IgG) and almost 40% (39.7%) exhib-
ited focal neurological signs [42]. Taken together, these 
findings indicate that in the African continent, there is a 
high variability T. gondii infection prevalence, which can 
go from residual values to very high levels. These differ-
ences can be associated with the socioeconomic condi-
tions, including the efficacy of health systems and health 
education and population traditional culture, values, cus-
toms, and beliefs.
Although several studies argued for the role of geno-
types in the clinical expression of human toxoplasmosis 
and the geographical structure of Toxoplasma across 
continents, genetic data concerning T. gondii isolates 
from Africa are scarce. In a study performed in  HIV+ 
patients from Uganda, the genotype II (12/22) was the 
most commonly found, followed by the type I genotype 
(5/22). The less representative genotypes were non-III 
(3/22) and type III (2/22) [39].
Toxoplasmosis in neonates and infants
Women at risk of transmitting congenital toxoplasmo-
sis include immunocompetent women when becom-
ing newly infected during pregnancy or challenged with 
atypical parasite strains, as well as, immunosuppressed 
mothers with HIV/AIDS when the reactivation of brady-
zoites occur during pregnancy [2, 15, 43]. Women that 
have acquired T. gondii infection before pregnancy have 
a limited risk of inducing a congenital infection. Primary 
infection during pregnancy does not cause specific symp-
toms, being unnoticed in most of the women, or lead to 
some transient low to mild symptoms that usually are 
not taken into consideration by the patient. In African 
countries, dating Toxoplasma infection during preg-
nancy is difficult, and the use of specific serology and the 
respective follow-up is often not extended to all pregnant 
women [44].
According to earlier studies in southern Africa, T. 
gondii seroprevalence among pregnant women ranges 
between 15 and 23% [39, 45, 46] and HIV-Toxoplasma 
co-infection was about 8% [47]. However, in sub-Saha-
ran Africa, more recent studies among pregnant women 
pointing through T. gondii-seroprevalences ranging 
between 5.9% and 85.5%. [48, 49]. As a consequence of 
the very high levels of T. gondii transmission among the 
Nigerian population (78%), Toxoplasma infection during 
pregnancy was about 30% [50, 51], representing a serious 
threat for congenital infection.
The risk factors for becoming infected have been iden-
tified. Eating raw meat, unwashed fresh vegetables or 
fruits, and undercooked food, drinking unpasteurized 
milk, and the proximity to cats seems to be predictors of 
possible infections [44]. Even so, the prevalence of Toxo-
plasma infection in pregnancy appears to be an under-
estimated public health concern in Africa, highlighting 
the urgent need for further research. Furthermore, the 
awareness of toxoplasmosis and its mode of transmission 
among women and, in particular, pregnant women seems 
to be limited [12, 52].
The risk of vertical transmission to the fetus, as a con-
sequence of crossing the placental barrier by tachyzoites, 
increases during pregnancy, and about 60% to 81% of 
the infections by T. gondii occur during the last trimes-
ter [2, 53]. However, the disease is more severe in the 
early stages of pregnancy, depending on parasite viru-
lence and of the infected T. gondii genotype. In the first 
trimester, the rate of infection can range from 15% to 
25% [10, 25, 54–57]. Congenital toxoplasmosis has been 
associated with a wide range of adverse outcomes, which 
includes spontaneous miscarriage, stillbirth, ocular dis-
ease, and neurologic and neurocognitive deficits. The 
most frequent presentation of congenital toxoplasmosis 
comprises of hydrocephalus, chorioretinitis, and cer-
ebral calcifications. In up to 80% of cases, the infection 
remains asymptomatic after birth, but infants may later 
present mental retardation and learning and visual disa-
bilities [2, 12, 53]. In upper-middle-income countries, the 
incidence of congenital hydrocephalus is at 0.5 cases per 
1000 live births, whereas in Africa and Latin America the 
incidence of neonatal hydrocephalus was estimated to be 
around 145 and 316 per 100.000 births, respectively [58, 
59]. In Nigeria it was determined that abortion occurred 
in 41.6% to 60% of pregnant women presenting anti-Tox-
oplasma antibodies, stillbirth happened in 6.8% to 61.5% 
of the cases, and neonatal death in 62.5%. Ocular prob-
lems occurred in 29.4% of newborns [60–62]. Torgerson 
and Mastroiacovo [63] estimated per 1000 live births the 
incidence of congenital cases accounting for 2–2.4 to 
13–15 of all Disability-Adjusted Life Years (DALYs) for 
the African continent, despite several African countries 
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have not reported  cases of congenital toxoplasmosis or 
seroprevalence data. Infants can also acquire primary 
Toxoplasma infection after birth and develop severe dis-
ease [3, 35, 64].
In a recent study in Tunisia, T. gondii isolated from the 
amniotic fluid and placenta of women that had an acute 
infection during pregnancy was revealed to be of the type 
II genotype [65]. However, no other published studies on 
T. gondii genotypes occurring on the African continent 
were found, especially in sub-Saharan African countries.
Toxoplasma infection in immunocompetent 
patients
Studies conducted in immunocompetent individuals liv-
ing in European countries or North America found that 
primarily acquired T. gondii infection is asymptomatic 
and self-limited in more than 80% of individuals [3, 66]. 
In a few cases, patients may present fever or cervical 
lymphadenopathy, sometimes associated with myalgia, 
asthenia, or other non-specific clinical signs that can be 
misdiagnosed with different clinical conditions, exhibit-
ing similar symptoms. The knowledge of the neuropa-
thology caused by Toxoplasma is progressing. [3, 57, 
67–69]. The immune response of chronically infected 
patients is mainly characterized by interferon-γ produc-
tion which induces the activation of indoleamine-2,3-di-
oxygenase leading to tryptophan (amino acid essential for 
serotonin biosynthesis) depletion, increase of kynurenic 
acid, and decrease of serotonin. Moreover, high tyrosine 
hydrolase activity directs dopamine release. Thus, high 
levels of kynurenic acid and dopamine, along with low 
amounts of serotonin are associated with cognitive dys-
functions [3].
Schizophrenia is a serious psychiatric disorder with 
a lifetime prevalence of approximately 1% and is rated 
as the 9th most common cause of disability all over the 
world [67]. Since 1953, more than 19 studies were done 
in patients with schizophrenia and other severe psychi-
atric disorders, testing for antibodies against T. gondii. Of 
these, 18 studies found patients with a higher frequency 
of anti-T. gondii antibodies, and in 11 out of 18, the asso-
ciation was statistically significant [57]. These conditions 
are indicated as the leading cause of disability in the 
world, accounting for 22.7% of DALYs [69].
A systematic review on the relationship between Toxo-
plasma infection and epilepsy concluded that this para-
sitic infection should be an epilepsy risk factor and that 
there is a need to conduct more studies to determine 
the real impact of T. gondii infection on epilepsy [70, 
71]. Moreover, studies conducted in Turkey and USA, in 
patients with cryptogenic epilepsy which aimed to evalu-
ate its possible relationship with T. gondii found 54% and 
75% of these patients infected with Toxoplasma, respec-
tively [72, 73].
In Southeast Africa, there is a scarcity of studies aim-
ing to define the relationship between epilepsy and Tox-
oplasma infection. A multicenter study conducted in 
Kenya, South Africa, Uganda, Tanzania, and Ghana in a 
total of 1711 individuals with active convulsive epilepsy 
found an odds ratio of 1.39 with previous exposure to T. 
gondii [74]. Moreover, studies from Kenya and other Afri-
can countries concluded that in addition to Toxoplasma 
infection, malaria, onchocerciasis, neurocysticercosis, 
and toxocariasis also might be involved in the pathogen-
esis of epilepsy [75, 76]. There is also evidence of possible 
association with some neurodegenerative disorders, such 
as Parkinson and Alzheimer diseases, in which the prev-
alence of Toxoplasma infection is around 85% and 66%, 
respectively [3, 77–81]. Suicidal behaviour is also a com-
mon problem in southeast Africa. A study from South 
Africa found that 3.2% of adolescents attempted to com-
mit suicide, 5.8% planned, and 7.2 reported ideation [82]. 
In Zambia, acute psychotic syndrome is the most com-
mon outpatient diagnosis, followed by schizophrenia, 
substance use disorder, and dementia [83]. Although T. 
gondii infection was considered a potential risk factor for 
suicide attempts [84], no studies exist reporting possible 
links between suicide attempts and Toxoplasma infection 
in Africa.
Burden of pathological disorders related possibly 
to Toxoplasma infection in Mozambique
Mozambique is a low-income country located in South-
east Africa, with 28.8 million people, a child mortality 
rate of 57.9‰, an adult literacy rate of 60.7%, and with 
most of the population (about 66%) living in rural areas 
[85]. According to the United Nations Development Pro-
gramme [86], this country ranks 180th on the human 
development index, which points towards a high unmeet 
in health care performance, low education levels, and 
basic living standards [87]. The national health system 
covers only 50% of the population, and according to the 
Mozambique Poverty Reduction Action Plan 2011–2014 
[88] 65% of the population have access to a health unit 
facility within 45 min walking distance of their homes. 
Despite natural fluctuations according to geographical 
settings, tuberculosis, HIV, malaria, neglected tropical 
diseases, in addition to respiratory and diarrheal dis-
eases, still are significant causes of morbidity and mor-
tality in Mozambique and among Southeastern African 
countries [87, 89–91] Furthermore, non-infectious dis-
eases, including cardiovascular diseases, cancer, chronic 
respiratory diseases, and diabetes also accounts for dis-
ease burden in Mozambique [92].
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In 2018, the prevalence of HIV in Mozambique was 
12.6% in the age group of 15 to 49 years-old and 45,000 
AIDS deaths [93], with nearly 2.2 million people living 
with HIV infection [94, 95]. Together with some of the 
neighboring countries, such as Eswatini, South Africa, 
Zimbabwe, Zambia, Malawi, and Tanzania, Mozambique 
is among the top ten countries presenting the highest 
prevalence of HIV in the world, which ranges from 6.5% 
to 27.2% [91].
Toxoplasma gondii infection can also be related to 
mental disorders in immunocompetent individuals and 
in immunocompromised patients, in addition to the neu-
rologic disorders of congenital toxoplasmosis. There was 
a significant improvement in the Mozambique mental 
health services, reaching rates of 0.59 mental health out-
patient facilities and 0.09 psychiatric hospitals for 100,000 
persons [96]. Mozambique has a suicide rate of 4.9 and a 
total of 1412 suicides per year, being in the 134 position 
in the global suicide rank [97]. However, this country has 
no published national suicide statistics. Even so, a cross-
sectional study performed in unnatural death, recorded 
from 2000–2009 at the Forensic Services in Maputo 
Central Hospital, reported 9% of suicide [98]. Epilepsy 
affects 50 million people worldwide, and about 80% live 
in low-income countries [99]. According to a previous 
study, Mozambique has a prevalence of 1.6% for epilepsy, 
pointing out to more than 400,000 individuals living with 
epilepsy [100]. However, most of these patients seemed 
to be children and adolescents [101]. Hydrocephalus is a 
serious problem in sub-Saharan Africa and despite there 
is little information about this disorder, it was predicted 
that in Mozambique an incidence of 2900 to 4800 cases 
of neonatal hydrocephalus occur per year [102]. Despite 
the high rates of HIV infection in Southeast Africa, 
including Mozambique, the high incidence of hydroceph-
alus in sub-Saharan Africa and Mozambique, and the 
high prevalence of mental disorders, Toxoplasma infec-
tion still is overlooked in Mozambique. According to the 
International Agency for the Prevention of Blindness 
[103] in Mozambique, sight disease affects more than 
300,000 persons from Maputo (capital of Mozambique) 
and Inhambane province, most of the cases are reported 
as cataract, glaucoma, and trachoma. Despite these num-
bers, there is no study or report about the incidence of 
ocular toxoplasmosis in Mozambique.
Though, little is known about the burden of toxoplas-
mosis in Southeastern Africa and Mozambique. In par-
ticular, the identification of risk factors, the genetic 
diversity of the parasite, as well as, Toxoplasma asso-
ciation with HIV, was not examined, the incidence of 
Toxoplasma infection in pregnant women, and the rela-
tionship with hydrocephalus and neuropsychiatric disor-
ders, such as epilepsy, schizophrenia, suicidal behaviors, 
mood disorders, obsessive-compulsive disorder, and gen-
eralized anxiety [104] among other conditions, was not 
examined.
Toxoplasma infection in Mozambique
Although T. gondii is commonly associated with immu-
nodeficiency disorders, a limited number of studies have 
been performed in Africa and, to the best of our knowl-
edge, nobody has previously investigated the risk of 
reactivation of latent T. gondii infection in Mozambique 
 HIV+ patients, for example. However, in the last decade a 
cross-sectional study in  HIV+/AIDS patients performed 
in Maputo (Mozambique) found a 46% prevalence of anti-
Toxoplasma IgG, pointing towards a latent Toxoplasma 
infection among almost half of  HIV+/AIDS patients. This 
study also identified the regular consumption of cattle 
meat, breeding cats and dogs, and regular contact with 
the soil as risk factors to acquire Toxoplasma infection 
[11]. Another study aiming to assess clinic-pathological 
discrepancies in the diagnosis of causes of death in HIV 
infected adults from Mozambique found that none of 
the 8/73 (9.6%) cases of toxoplasmosis confirmed in  the 
autopsy were clinically suspected, indicating 100% of 
major clinical discrepancies [105] (Fig. 1).
Congenital toxoplasmosis can cause miscarriage, 
blindness, deafness, hydrocephalus, and brain dam-
age. Newborns may appear healthy at birth, but later in 
life can suffer from eye diseases, or have cognitive dif-
ficulties. Moreover, screening of Toxoplasma infection 
during pregnancy and specific treatment resulted in a 
decrease of T. gondii transmission from mother to child 
and a consequent reduction of clinical sequelae in infants 
[43]. There are no published data on the burden of con-
genital toxoplasmosis in Mozambique, nor its relation 
with hydrocephalus, seizures and mental retardation, 
which are disorders prevalent in Mozambique as already 
referred. A previous study performed by Sitoe et  al. 
[106] in 150 pregnant women seeking the first trimes-
ter prenatal care in Maputo Central Hospital (Maputo, 
Mozambique) reported an overall prevalence of 18.7% 
of Toxoplasma IgG antibodies with the occurrence of 
31.3% in  HIV+ pregnant women and 10.9% in immuno-
competent pregnant women (Fig. 1). Taking into account 
the dimension of this study, the findings indicate the less 
than 25% of the pregnant woman had previous contact 
with T. gondii and that part of these women were Toxo-
plasma/HIV co-infected. In the same study, only one 
woman presenting significant levels of anti-Toxoplasma 
IgM was found [106], pointing towards a lower occur-
rence of active T. gondii infection during the first trimes-
ter of pregnancy in Maputo. The incidence of neonatal 
hydrocephalus in Mozambique was estimated to be 3–5 
cases per 1000 live births [102], which leads to severe 
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disability as is a significant cause of morbidity and mor-
tality. However, the proportion of children that acquired 
T. gondii infection during pregnancy and developed con-
genital toxoplasmosis is not known. Similarly, there are 
no studies available on the importance of T. gondii infec-
tion in ocular disease, mental retardation, schizophre-
nia and epilepsy either in children or in adults living in 
Mozambique.
Moreover, in Mozambique, there are no available data 
on the clinical expression and severity of human toxo-
plasmosis in the diverse segments of the population and 
across the different regions, identification of T. gondii 
strains that circulate in the country, and on the dynamics 
of parasite transmission.
Fig. 1 Toxoplasma studies reported in Mozambique. Map indicating the population of each Mozambique province following the 2017 census [85], 
and where the published studies were made. Abbreviation: M, millions
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Conclusions
Toxoplasma gondii is a globally widespread parasite that 
invades and chronically persists in the central nervous 
system of infected individuals. The complexity of this 
infection is a consequence of the intimate relationship 
established between the parasite and the host immunity, 
which can lead to persistent infections of limited patho-
genesis. Further advances in the understanding of Toxo-
plasma infection have found a link between this parasite, 
mental and mood disorders, and suicidal behavior. How-
ever, this parasitic infection should not be evaluated from 
a restricted anthroponotic perspective since wild and 
domestic animals are involved in parasite genetic recom-
bination and transmission. Moreover, molecular studies 
contributed to identifying different parasite strains asso-
ciated with virulence levels and implicated in the spe-
cific clinical characteristics of the disease. Thus, it is of 
utmost importance to estimate the incidence of T. gon-
dii infection and toxoplasmosis among the Mozambique 
population. The few available studies reflect the reality 
of Maputo, the Mozambique capital, and comprehensive 
information for the entire country is missing. Further-
more, understanding the extension of T. gondii infec-
tion and the risk factors associated is a pre-requisite for 
the development of effective control measures. Then, it 
is urgent to develop and implement research programs 
directed to the gaps of knowledge, which include up-to-
date information on T. gondii geographical distribution, 
the incidence and risk factors of immunocompetent, con-
genital, and perinatal infection, the occurrence of ocular 
toxoplasmosis, the association of Toxoplasma infection 
with mental and neurodegenerative disorders, as well as 
the identification of T. gondii genotypes circulating in 
Mozambique and its relation to morbidity and mortality. 
The research priorities identified for Mozambique can be 
an excellent starting point to inspire neighboring east-
ern African countries to foster research, in particular on 
this parasitic infection, and thus increasing knowledge in 
scientific and clinical areas, promoting the reduction of 
social impacts related to disability and consequent labor 
hours lost and advance the social-economic conditions.
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